Oncolytics Biotech
ONCY
33 hedge funds and large institutions have $1.38M invested in Oncolytics Biotech in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
0.33% more ownership
Funds ownership: 1.53% → 1.86% (+0.33%)
4% less capital invested
Capital invested by funds: $1.43M → $1.38M (-$52.2K)
6% less funds holding
Funds holding: 35 → 33 (-2)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$361K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$79.4K |
| 3 |
Renaissance Technologies
New York
|
+$27.1K |
| 4 |
SS
Simplicity Solutions
Minneapolis,
Minnesota
|
+$18.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$42K |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$41K |
| 3 |
BAM
Brave Asset Management
Summit,
New Jersey
|
-$32.8K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$25.9K |
| 5 |
Rockefeller Capital Management
New York
|
-$9K |
ONCY Hedge Fund Activity: Q1 2023 in Review
33 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2023, worth a combined $1.38M — down 3.7% from $1.43M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ONCY and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 12 added.
The largest buyer was Osaic Holdings, adding an estimated $361K. The largest seller was Millennium Management, exiting entirely with an estimated $42K sold.
- 33 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2023, down from 35 in Q4 2022.
- Funds reported $1.38M of Oncolytics Biotech stock for Q1 2023, down 3.7% quarter-over-quarter.
- 5 funds opened new Oncolytics Biotech positions in Q1 2023 and 6 closed out, a net change of -1 holder.
- The largest Oncolytics Biotech buyer in Q1 2023 was Osaic Holdings, an estimated $361K added.
- The largest Oncolytics Biotech seller in Q1 2023 was Millennium Management, an estimated $42K sold.
Based on aggregated 13F filings for Q1 2023.